An International Multicenter Open-label Randomized Trial of the Efficacy, Pharmacokinetics, Safety, and Immunogenicity of BCD-100 (JSC BIOCAD, Russia) as Monotherapy in Patients With Unresectable/Metastatic Melanoma.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 07 Sep 2018
At a glance
- Drugs Adalimumab (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Acronyms MIRACULUM
- Sponsors Biocad
- 29 Aug 2018 Planned End Date changed from 30 Aug 2018 to 1 Dec 2019.
- 11 Mar 2018 Status changed from recruiting to active, no longer recruiting.
- 04 Sep 2017 New trial record